Business Description
Medigene AG
ISIN : DE000A40ESG2
Share Class Description:
MDGEF: Namen-Akt. nach KapitalherabsetzungCompare
Compare
Traded in other countries / regions
MDG1.GermanyMDGEF.USAMDG2.Austria IPO Date
2013-09-05Description
Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.
Financial Strength
| Name | Current | Vs Industry | Vs History |
|---|
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
FCF Margin % | -300.43 | |||||
OCF Margin % | -190.59 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-Forward-EBIT | -0.93 | |||||
EV-to-Forward-EBITDA | -0.93 | |||||
EV-to-Forward-Revenue | 1.34 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:MDGEF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Medigene AG Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 8.057 | ||
| EPS (TTM) ($) | -1.316 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -0.17 | ||
| 3-Year Sortino Ratio | -0.28 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR ($) | - | ||
| 20-Day SMA ($) | 2.59 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 2.59 - 2.59 | ||
| Shares Outstanding (Mil) | 14.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Medigene AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Medigene AG Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-09 | In 131 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-19 | In 49 days | ||
| Second quarter earnings results for 2026 | 2026-08-19 | In 49 days | ||
| First quarter earnings results for 2026 | 2026-07-10 | In 9 days | ||
| General meeting for 2025 | 2026-07-10 | In 9 days | ||
| Annual report for 2025 | 2026-07-03 | In 2 days | ||
| First quarter earnings results for 2026 | 2026-05-22 | 2.59 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-05-15 10:00 | 2.59 (+0.00%) | ||
| Annual report for 2025 | 2026-05-15 | 2.59 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-05-15 | 2.59 (+0.00%) |
Show
Entries
Medigene AG Frequently Asked Questions
What is Medigene AG(MDGEF)'s stock price today?
The current price of MDGEF is $2.59. The 52 week high of MDGEF is $2.59 and 52 week low is $2.59.
When is next earnings date of Medigene AG(MDGEF)?
The next earnings date of Medigene AG(MDGEF) is 2026-07-10 Est..
Does Medigene AG(MDGEF) pay dividends? If so, how much?
Medigene AG(MDGEF) does not pay dividend.
Guru Commentaries on OTCPK:MDGEF
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Roivant and Sinovant Launch Cytovant Sciences in Partnership with Medigene to Develop Cellular Therapies in Asia | 2019-04-04 |
Articles on Medigene AG
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers